Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. JAMA Netw Open 2023 Dec 01;6(12):e2347950
Date
12/18/2023Pubmed ID
38109114Pubmed Central ID
PMC10728762DOI
10.1001/jamanetworkopen.2023.47950Scopus ID
2-s2.0-85180310408 (requires institutional sign-in at Scopus site) 1 CitationAbstract
IMPORTANCE: Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response using tyrosine kinase inhibitors (TKIs) can safely attempt to stop their use. As these medications are very costly, this change in treatment protocols may result in large savings.
OBJECTIVE: To estimate future savings from attempting to stop TKI use among patients with CML who have deep molecular response.
DESIGN, SETTING, AND PARTICIPANTS: A microsimulation model was developed for this decision analytical modeling study to estimate costs for US adults moving from using a TKI, to attempting discontinuation and then reinitiating TKI therapy, if clinically appropriate. Estimates were calculated for US patients who currently have CML and simulated newly diagnosed cohorts of patients over the next 30 years.
EXPOSURE: Attempting to stop using a TKI.
MAIN OUTCOMES AND MEASURES: Estimated savings after attempted discontinuation of TKI use.
RESULTS: A simulated population of individuals with CML in 2018 and future populations were created using estimates from the SEER*Explorer website. The median age at diagnosis was 66 years for men and 65 years for women. Between 2022 and 2052, the savings associated with eligible patients attempting discontinuation of TKI therapy was estimated at more than $30 billion among those currently diagnosed and over $15 billion among those who will develop CML in the future, for a total savings of over $54 billion by 2052 for drug treatment and polymerase chain reaction testing. The estimate is conservative as it does not account for complications and other health care-associated costs for patients continuing TKI therapy.
CONCLUSIONS AND RELEVANCE: The findings of this decision analytical modeling study of patients with CML suggest that attempting discontinuation of TKI therapy could save over $54 billion during the next 30 years. Further education for patients and physicians is needed to safely increase the number of patients who can successfully attain treatment-free remission.
Author List
Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KEAuthors
Ehab L. Atallah MD Professor in the Medicine department at Medical College of WisconsinKathryn Eve Flynn PhD Vice Chair, Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultFemale
Health Care Costs
Humans
Income
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Patients
Protein Kinase Inhibitors
